August 20, 2010

The CLEAR Study: A 5-day, 3-g Loading Dose of Mycophenolate Mofetil versus Standard 2-g Dosing in Renal Transplantation


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Although mycophenolate mofetil (MMF) is prescribed at a standard dose for all patients, there are studies showing that there is a level of MMF exposure at which the risk of acute rejection is reduced. Some studies have compared therapeutic drug monitoring to fixed doses of MMF. In contrast, this open-label multicenter randomized controlled trial compared two different fixed doses of MMF in the first five days post-transplant. Higher MMF dosing early post-transplant showed a trend towards fewer acute rejection and graft loss at six months, but did not reach statistical significance.

Free full text kindly provided by the American Society of Nephrology.

Renal Transplantation